Please wait a minute...
文章检索
预防医学  2023, Vol. 35 Issue (11): 992-996    DOI: 10.19485/j.cnki.issn2096-5087.2023.11.017
  疾病监测 本期目录 | 过刊浏览 | 高级检索 |
2008—2022年崇川区疑似预防接种异常反应监测结果
顾红1, 侯晓艳2, 祁志刚1, 吴明1
1.南通市崇川区疾病预防控制中心免疫规划科,江苏 南通 226001;
2.南通市疾病预防控制中心,江苏 南通 226001
Surveillance of suspected adverse events following immunization in Chongchuan District from 2008 to 2022
GU Hong1, HOU Xiaoyan2, QI Zhigang1, WU Ming1
1. Department of Immunization Planning, Chongchuan District Center for Disease Control and Prevention, Nantong, Jiangsu 226001, China;
2. Nantong Center for Disease Control and Prevention, Nantong, Jiangsu 226001, China
全文: PDF(833 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 了解2008—2022年江苏省南通市崇川区疑似预防接种异常反应(AEFI)发生情况,为疫苗接种安全性评价提供依据。方法 通过中国免疫规划信息系统AEFI监测系统收集2008—2022年崇川区AEFI监测资料,包括AEFI病例的人口学信息、预防接种史、实验室检测资料、AEFI发病和临床资料;描述性分析2008—2022年崇川区AEFI发生特征和报告发生率。结果 2008—2022年崇川区AEFI报告发生率呈下降趋势(P<0.05),年均报告发生率为50.85/10万剂。免疫规划疫苗AEFI报告发生率为74.67/10万剂,高于非免疫规划疫苗的20.35/10万剂(P<0.05)。报告发生的AEFI以一般反应为主,1 937例,报告发生率为44.21/10万剂;异常反应274例,报告发生率为6.25/10万剂;偶合症17例,报告发生率为0.39/10万剂;无疫苗质量事故和接种事故报告。经皮下注射和肌内注射途径的疫苗AEFI报告发生率较高,分别为75.05/10万剂和47.40/10万剂;口服途径的报告发生率较低,为16.41/10万剂。AEFI报告发生率居前五位的疫苗为无细胞百白破b型流感嗜血杆菌(结合)联合疫苗(312.01/10万剂)、7价肺炎球菌多糖结合疫苗(292.14/10万剂)、乙脑灭活疫苗(248.37/10万剂)、ACYW135群脑膜炎球菌多糖疫苗(240.67/10万剂)和麻疹风疹联合减毒活疫苗(229.31/10万剂)。一般反应以发热、红肿和硬结等为主,1 878例占96.95%;异常反应以过敏性皮疹为主,241例占87.96%。91.34%的AEFI发生于接种后24 h内。AEFI报告3个月后随访,99.73%的病例痊愈。结论 2008—2022年崇川区AEFI报告发生率呈下降趋势。AEFI类型以一般反应为主,预后良好,疫苗接种安全性较高。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
顾红
侯晓艳
祁志刚
吴明
关键词 疑似预防接种异常反应监测疫苗    
AbstractObjective To investigate the incidence of suspected adverse events following immunization(AEFI) in Chongchuan District, Nantong City, Jiangsu Province from 2008 to 2022, so as to provide insights into safety assessment of vaccines. Methods The data on AEFI surveillance in Chongchuan District from 2008 to 2022 were collected through the National Immunization Program Information Management System of China, including demographics, history of vaccination, laboratory tests, incidence of AEFI and clinical characteristics. The epidemiological, clinical characteristics and reported incidence of AEFI were analyzed in Chongchuan District from 2008 to 2022 using a descriptive epidemiological method. Results The reported incidence of AEFI in Chongchuan District from 2008 to 2022 appeared a tendency towards a decline (P<0.05), and the annual average reported incidence was 50.85/105. The incidence of AEFI associated with vaccines included in the national immunization program was significantly higher than that caused by vaccines that were not included in the national immunization program (74.67/105 vs. 20.35/105, P<0.05). General reaction was the predominant type of AEFI (1 937 cases, 44.21/105), and there were 274 cases with abnormal reactions (6.25/105) and 17 cases with coincident syndromes (0.39/105); however, no vaccine quality or vaccination accidents occurred. A high incidence rate was seen in AEFI associated with vaccines administered by subcutaneous (75.05/105) and intramuscular injection (47.40/105), and a low incidence rate was found in AEFI associated with vaccines administered orally (16.41/105). The five highest reported incidence rates of AEFI were found for the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine (312.01/105), 7-valent pneumococcal polysaccharide-protein conjugate vaccine (292.14/105), inactivated Japanese encephalitis vaccine (248.37/105), Group ACYW135 meningococcal polysaccharide vaccine (240.67/105) and combined live vaccine for measles and rubella (229.31/105). The general reactions mainly included fever, redness and swelling and induration (1 878 cases, 96.95%), and abnormal reactions mainly included allergic skin rash (241 cases, 87.96%). In addition, 91.34% of AEFI occurred within 24 hours after vaccination, and 99.73% of cases with AEFI were cured during the 3-month follow-up. Conclusions The reported incidence of AEFI appeared a tendency towards a decline in Chongchuan District from 2008 to 2022. General reaction was the predominant type of AEFI, and all AEFI showed a good prognosis. The safety of vaccines was high in Chongchuan District from 2008 to 2022.
Key wordssuspected adverse event following immunization    surveillance    vaccine
收稿日期: 2023-07-31      修回日期: 2023-10-08      出版日期: 2023-11-10
中图分类号:  R186  
基金资助:中国肝炎防治基金会2020年度中国乙肝防控科研基金(YGFK20200038)
通信作者: 侯晓艳,E-mail:369511306@qq.com   
作者简介: 顾红,本科,副主任医师,主要从事免疫规划工作
引用本文:   
顾红, 侯晓艳, 祁志刚, 吴明. 2008—2022年崇川区疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(11): 992-996.
GU Hong, HOU Xiaoyan, QI Zhigang, WU Ming. Surveillance of suspected adverse events following immunization in Chongchuan District from 2008 to 2022. Preventive Medicine, 2023, 35(11): 992-996.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2023.11.017      或      http://www.zjyfyxzz.com/CN/Y2023/V35/I11/992
[1] 张丽娜,李克莉,杜雯,等. 2019年中国疑似预防接种异常反应监测[J]. 中国疫苗和免疫,2021,27(4):438-445.
[2] 张丽娜,李克莉,杜雯,等. 2018年中国疑似预防接种异常反应监测[J]. 中国疫苗和免疫,2020,26(4):363-371.
[3] 张丽娜,李克莉,李燕,等. 2020年中国疑似预防接种异常反应监测[J]. 中国疫苗和免疫,2022,28(2):208-217.
[4] 侯晓艳,廉丽华,倪杰,等. 2008—2020年南通市疫苗接种安全性分析与评估[J]. 职业与健康,2022,38(19):2672-2677,2682.
[5] 吴瑛,李瑞平,高彩红.2010—2020年上海市奉贤区南桥镇疑似预防接种异常反应监测数据分析[J]. 职业与健康,2022,38(5):654-658.
[6] 杨菊,马紫妍,王洁,等. 2015—2021年郑州市二七区疑似预防接种异常反应监测结果分析[J]. 华南预防医学,2022,48(6):773-776.
[7] 王晓柳,汤元妃. 2018—2021年武义县疑似预防接种异常反应监测结果[J]. 预防医学,2022,34(11):1167-1171,1177.
[8] 杜哲群,胡洁,沈国初,等. 嘉兴市8月龄儿童接种MMR、MR疫苗疑似预防接种异常反应监测结果[J]. 预防医学,2020,32(11):1086-1090.
[9] 吴琳琳,刘捷宸,李智,等. 2011—2018年上海市含麻疹成分疫苗疑似预防接种异常反应监测分析[J]. 上海预防医学,2021,33(4):291-295.
[10] 沈金花,陈文花,顾士康,等. 2011—2016年松江区预防接种不良事件监测分析[J]. 现代预防医学,2018,45(10):1890-1894.
[11] 胡丽楠,李岩,郭爽,等. 2007—2019年哈尔滨市疑似预防接种异常反应监测分析[J]. 现代预防医学,2020,47(12):2258-2262.
[12] 张英,罗美玲. 长沙市儿童免疫规划疫苗延迟接种现状及影响因素分析[J]. 预防医学,2021,33(3):280-283.
[1] 刘艳, 沈建勇, 张超, 孙秀秀, 王雨达, 郑佳仪, 张子喆. 2012—2022年湖州市百日咳流行特征分析[J]. 预防医学, 2023, 35(9): 811-813.
[2] 张超, 罗小福, 刘艳, 沈建勇, 徐秦儿, 韩利萍, 马力. 湖州市老年人接种流感灭活疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(8): 701-704.
[3] 陈敏, 文金生. 腺病毒载体的黄病毒属病毒疫苗研究进展[J]. 预防医学, 2023, 35(8): 677-681.
[4] 马艳艳, 陈小劲, 赵月. 朝阳区3~6岁儿童体质健康调查[J]. 预防医学, 2023, 35(7): 615-619.
[5] 徐杰, 陈棕棕, 骆水娟, 李欢龙. 富阳区市售食品食源性致病菌监测结果[J]. 预防医学, 2023, 35(7): 624-627.
[6] 潘晓东, 韩见龙, 陈苘. 鸡肉中多种抗生素超高效液相-静电场轨道阱高分辨质谱检测方法[J]. 预防医学, 2023, 35(5): 456-459.
[7] 李改芳, 冯勤梅, 仇丽霞. 基于技术接受与使用统一理论2的妇科门诊就诊患者HPV疫苗接种行为研究[J]. 预防医学, 2023, 35(4): 295-297,326.
[8] 钱晓萍, 罗小福, 凌健. 湖州市疫苗接种相关的过敏性皮疹监测结果[J]. 预防医学, 2023, 35(4): 339-341.
[9] 窦倩如, 黄翠敏, 曹霞, 樊利春. 海南省女性HPV疫苗相关知识和接种意愿调查[J]. 预防医学, 2023, 35(4): 359-364.
[10] 钱晓萍, 凌健, 刘腾. 吴兴区6岁以下儿童手足口病流行特征分析[J]. 预防医学, 2023, 35(3): 243-245,249.
[11] 赵冲, 施文文. 富阳区监测哨点医院急诊就诊伤害病例特征分析[J]. 预防医学, 2023, 35(2): 155-157,161.
[12] 陈劲华, 楼灵巧, 陶静波, 万斌斌, 成航, 贾建伟, 骆淑英. 义乌市百日咳病例流行病学特征分析[J]. 预防医学, 2023, 35(11): 981-984.
[13] 范琦淇, 陈慈玉, 孙晓宁, 吴蔚然, 王娟. 高血压患者家庭血压监测调查[J]. 预防医学, 2023, 35(11): 948-952.
[14] 李小勇, 段蕾蕾, 武轶群, 钟节鸣, 林鸿波, 沈鹏, 赵磊. 鄞州区伤害智能监测系统介绍及应用[J]. 预防医学, 2023, 35(11): 1009-1012.
[15] 王炸亚, 叶莉霞, 吴锋. 宁波市2018—2021年出生儿童肠道病毒71型疫苗接种情况分析[J]. 预防医学, 2023, 35(10): 895-898.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed